Clinical Trial Search

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001

Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005

Primary: Percentage Change From Baseline in the LDL-C/HDL-C Ratio — -50.9; -53.0; -37.6; -42.4 Percentage Change — p=<0.001

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — -0.84; -64.98 percent change — p=<0.0001

Primary: Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) — -40.78; -43.25 percent change

Primary: The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol. — 3.2; -0.3 mg/dL — p=0.0018

Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants

Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -51.8; -3.9; -48.2; 0.8 percent change — p=<0.0001

Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001

Primary: Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C) — -38.8; -19.2; 0.9 Percent change — p=<0.001

Primary: Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point — -16; -36; -53; -47 percent change — p=0.0343

Primary: Basal HDL-cholesterol Level — 39.5 mg/dL

Primary: Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 — -34.8; -22.7 percent

Primary: Percent Change From Baseline in Fasting TG at Week 24 — 7.55; -43.67; -49.01; -55.57 percentage change — p=<.0001

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin…

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL